Market research
RLMD Relmada Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 494M
- P/E ratio
- Not available
- Analyst target
- 12.6667
- Dividend yield
- Not available
- Beta
- 0.83
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US75955J4022
- Market cap
- 494M
- P/E ratio
- Not available
- Analyst target
- 12.6667
- Dividend yield
- Not available
- Beta
- 0.83
About
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RLMD discussion.
5 years, 4 months ago
Relmada Therapeutics, Inc is currently in a long term downtrend where the price is trading 4.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Relmada Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 98.7% to $-59K since the same quarter in the previous year.
Finally, its free cash flow fell by 78.6% to $-7M since the same quarter in the previous year.
Based on the above factors, Relmada Therapeutics, Inc gets an overall score of 2/5.